Analyst’s Coverage of Generix (GNBT) Boosts Share Price
With the 10-year Treasury bond rates playing tug-of-war with investors in the stock market, analyst coverage can still spark growth in companies. Yesterday's 10-year note reached a 5-year high, peaking at 5.27 percent, guiding a stock market sell-off yesterday. Many investors feared the higher rates would increase borrowing cost and slow down the market.Rodman and Renshaw, a New York-based investment bank, was able to side track investors minds with a recent "Market Outperform" rating of Generix Biotechnology Corp. (NASDAQ: GNBT). Analyst Navdeep Jaikaria said the stock should reach a target price of $6 over the next 18 months. According to…